https://doi.org/10.4081/cdr.12.12911
A tale of A1298C mutation and recurrent Pulmonary Embolism: a rare association
Accepted: 10 September 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Pulmonary Embolism (PE) and Deep Venous Thrombosis (DVT) represent critical manifestations within the spectrum of Venous Thromboembolic Disease (VTE). The MTHFR A1298C gene mutation occurs in approximately 7% to 12% of individuals in North America, Europe, and Australia. It is less prevalent among Hispanic populations, with a frequency of 4% to 5%, and even lower in Chinese and Asian populations, where it ranges from 1% to 4%.
A 50-year-old male with a history of recurrent PE and long-term anticoagulation, despite effective anticoagulation, was not getting relieved. Genetic testing revealed a heterozygous MTHFR A1298C mutation which is very rare and elevated serum homocysteine levels, contributing to a hypercoagulable state. Comprehensive evaluation and management are essential to prevent further thromboembolic events in such patients.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
